Abstract
Prostate cancer treatment planning is largely dependent upon examination of core-needle biopsies. In current clinical practice, the microscopic architecture of the prostate glands is what forms the basis for prognostic grading by pathologists. Interpretation of these convoluted 3D glandular structures via visual inspection of a limited number of 2D histology sections is often unreliable, which contributes to the under- and over-treatment of patients. To improve risk assessment and treatment decisions, we have developed a workflow for non-destructive 3D pathology and computational analysis of whole prostate biopsies labeled with a rapid and inexpensive fluorescent analog of standard H&E staining. Our analysis is based on interpretable glandular features, and is facilitated by the development of image-translation-assisted segmentation in 3D (ITAS3D). ITAS3D is a generalizable deep-learning-based strategy that enables tissue microstructures to be volumetrically segmented in an annotation-free and objective (biomarker-based) manner without requiring real immunolabeling. To provide evidence of the translational value of a computational 3D pathology approach, we analyzed ex vivo biopsies (n = 300) extracted from archived radical-prostatectomy specimens (N = 50), and found that 3D glandular features are superior to corresponding 2D features for risk stratification of low-to intermediate-risk PCa patients based on their clinical biochemical recurrence (BCR) outcomes.
Significance We present an end-to-end pipeline for computational 3D pathology of whole prostate biopsies, showing that non-destructive pathology has the potential to enable superior prognostic stratification for guiding critical oncology decisions.
Competing Interest Statement
N.P.R., A.K.G., L.D.T., and J.T.C.L. are co-founders and shareholders of Lightspeed Microscopy Inc. A.M. is an equity holder in Elucid Bioimaging and in Inspirata Inc. In addition, he has served as a scientific advisory board member for Inspirata Inc, Astrazeneca, Bristol Meyers-Squibb and Merck. Currently, A.M. serves on the advisory board of Aiforia Inc. He also has sponsored research agreements with Philips, AstraZeneca, Boehringer-Ingelheim and Bristol Meyers-Squibb. A.M.s technology has been licensed to Elucid Bioimaging. He is also involved in a NIH U24 grant with PathCore Inc, and 3 different R01 grants with Inspirata Inc.
Funding Statement
The authors acknowledge funding support from the Department of Defense (DoD) Prostate Cancer Research Program (PCRP) through W81XWH-18-10358 (J.T.C.L, L.D.T. and J.C.V.), W81XWH-19-1-0589 (N.P.R.), W81XWH-15-1-0558 (A.M.) and W81XWH-20-1-0851 (A.M. and J.T.C.L.). Support was also provided by the National Cancer Institute (NCI) through K99 CA240681 (A.K.G.), R01CA244170 (J.T.C.L.), U24CA199374 (A.M.), R01CA249992 (A.M.), R01CA202752 (A.M.), R01CA208236 (A.M.), R01CA216579 (A.M.), R01CA220581 (A.M.), R01CA257612 (A.M.), U01CA239055 (A.M.), U01CA248226 (A.M.), and U54CA254566 (A.M.). Additional support was provided by the National Heart, Lung and Blood Institute (NHLBI) through R01HL151277 (A.M.), the National Institute of Biomedical Imaging and Bioengineering (NIBIB) through R01EB031002 (J.T.C.L.) and R43EB028736 (A.M.), the National Institute of Mental Health through R01MH115767 (J.C.V.), the VA Merit Review Award IBX004121A from the United States Department of Veterans Affairs (A.M.), the National Science Foundation (NSF) 1934292 HDR: I-DIRSE-FW (J.T.C.L.), the NSF Graduate Research Fellowships DGE-1762114 (K.W.B.) and DGE-1762114 (L.B.), the Nancy and Buster Alvord Endowment (C.D.K), and the Prostate Cancer Foundation Young Investigator Award (N.P.R.). The training and inference of the deep learning models were facilitated by the advanced computational, storage, and networking infrastructure provided by the Hyak supercomputer system, as funded in part by the student technology fee (STF) at the University of Washington. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation, the National Institutes of Health, the Department of Defense, the Department of Veterans Affairs, or the United States Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study approved by the University of Washington IRB, study number 00004980.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Example prostate images for testing ITAS3D codes and models are available in a GitHub repository at https://github.com/WeisiX/ITAS3D. Full 3D prostate imaging datasets are available upon reasonable request and with the establishment of a material-transfer or data-transfer agreement. Relevant clinical data for this study are provided in Supplementary Table 3.
